Chronic potentiation of cardiac L-type Ca2 channels by pirfenidone

Cardiovascular Research

Volumn 96, Issue 2, 2012, Pages 244-254

  Ramos Mondragón, Roberto ^a   Galindo, Carlos A ^a   García Castañeda, Maricela ^a   Sánchez Vargas, José L ^a   Vega, Ana V ^a   Gómez Viquez, Norma L ^a   Avila, Guillermo ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Action potential; Arrhythmia; Ion channel; Remodelling

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CALCIUM ION; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYTOKINE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PIRFENIDONE; POTASSIUM CHANNEL; REACTIVE OXYGEN METABOLITE; SODIUM CHANNEL; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED CALCIUM CHANNEL 1.2;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; MALE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACTION POTENTIALS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; LONG-TERM POTENTIATION; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; PYRIDONES; RATS; RECEPTOR CROSS-TALK; SECOND MESSENGER SYSTEMS; SODIUM CHANNELS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84867717143     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs248     Document Type: Article

References (38)

1. Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 2010;3:16.
2. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97.
3. Carter NJ. Pirfenidone. Drugs 2011;71:1721-1732.
4. Nakanishi H, Kaibori M, Teshima S, Yoshida H, Kwon A-H, Kamiyama Y et al. Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes. J Hepatol 2004;41:730-736.
5. Tsuchiya H, Kaibori M, Yanagida H, Yokoigawa N, Kwon A-H, Okumura T et al. Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. J Hepatol 2004;40:94-101.
6. Salazar-Montes A, Ruiz-Corro L, López-Reyes A, Castrejón-Gómez E, Armendáriz-Borunda J. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 2008;595:69-77.
7. Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 1999;18: 169-177.
8. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000;204:119-126.
9. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001;133:687-694.
10. Mirkovic S, Seymour A-ML, Fenning A, Strachan A, Margolin SB, Taylor SM et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 2002;135:961-968.
11. Lee KW, Everett TH 4th, Rahmutula D, Guerra JM, Wilson E, Ding C et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006;114:1703-1712.
12. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm 2010;7:1438-1445.
13. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006;34:327-334.
14. Ferreiro M, Petrosky AD, Escobar AL. Intracellular Ca2+ release underlies the development of phase 2 in mouse ventricular action potentials. Am J Physiol Heart Circ Physiol 2012;302:H1160-H1172.
15. Avila G, Medina IM, Jiménez E, Elizondo G, Aguilar CI. Transforming growth factorbeta1 decreases cardiac muscle L-type Ca2+ current and charge movement by acting on the Cav1.2 mRNA. Am J Physiol Heart Circ Physiol 2007;292:H622-H631.
16. Ramos-Mondragón R, Vega AV, Avila G. Long-term modulation of Na+ and K+ channels by TGF-b1 in neonatal rat cardiac myocytes. Pflugers Arch 2011;461:235-247.
17. Xu XP, Best PM. Increase in T-type calcium current in atrial myocytes from adult rats with growth hormone-secreting tumors. Proc Natl Acad Sci USA 1990;87:4655-4659.
18. Ellingsen O, Davidoff AJ, Prasad SK, Berger HJ, Springhorn JP, Marsh JD et al. Adult rat ventricular myocytes cultured in defined medium: phenotype and electromechanical function. Am J Physiol 1993;265:H747-H754.
19. Banyasz T, Lozinskiy I, Payne CE, Edelmann S, Norton B, Chen B et al. Transformation of adult rat cardiac myocytes in primary culture. Exp Physiol 2008;93:370-382.
20. Verheule S, Sato T, Everett T 4th, Engle SK, Otten D, Rubart-von der Lohe M et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004;94:1458-1465.
21. Méry PF, Pavoine C, Belhassen L, Pecker F, Fischmeister R. Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 1993;268:26286-26295.
22. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G. Species-and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol, Part A Mol Integr Physiol 2005;142:136-143.
23. Tamargo J, Caballero R, Gómez R, Delpón E. Cardiac electrophysiological effects of nitric oxide. Cardiovasc Res 2010;87:593-600.
24. Hulme JT, Lin TW-C, Westenbroek RE, Scheuer T, Catterall WA. Beta-adrenergic regulation requires direct anchoring of PKA to cardiac CaV1.2 channels via a leucine zipper interaction with A kinase-anchoring protein 15. Proc Natl Acad Sci USA 2003;100:13093-13098.
25. Hu H, Chiamvimonvat N, Yamagishi T, Marban E. Direct inhibition of expressed cardiac L-type Ca2+ channels by S-nitrosothiol nitric oxide donors. Circ Res 1997; 81:742-752.
26. Yang L, Liu G, Zakharov SI, Bellinger AM, Mongillo M, Marx SO. Protein kinase G phosphorylates Cav1.2 alpha1c and beta2 subunits. Circ Res 2007;101:465-474.
27. Buraei Z, Yang J. The b subunit of voltage-gated Ca2+ channels. Physiol Rev 2010;90: 1461-1506.
28. Chien AJ, Carr KM, Shirokov RE, Rios E, Hosey MM. Identification of palmitoylation sites within the L-type calcium channel b2a subunit and effects on channel function. J Biol Chem 1996;271:26465-26468.
29. Miriyala J, Nguyen T, Yue DT, Colecraft HM. Role of CaVbeta subunits, and lack of functional reserve, in protein kinase A modulation of cardiac CaV1.2 channels. Circ Res 2008;102:e54-e64.
30. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997;100:2146-2152.
31. Hopkins A, Mason J, Overington J. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006;16:127-136.
32. Dobrev D. Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target. Naunyn Schmiedebergs Arch Pharmacol 2010;381:195-206.
33. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000;101: 2631-2638.
34. Yue L, Feng J, Gaspo R, Li G-R, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;81:512-525.
35. Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 1999;85:428-436.
36. Carnes CA, Janssen PML, Ruehr ML, Nakayama H, Nakayama T, Haase H et al. Atrial glutathione content, calcium current, and contractility. J Biol Chem 2007;282: 28063-28073.
37. January CT, Riddle JM, Salata JJ. A model for early afterdepolarizations: induction with the Ca2+ channel agonist Bay K 8644. Circ Res 1988;62:563-571.
38. McDonough SI, Mori Y, Bean BP. FPL 64176 Modification of CaV1.2 L-type calcium channels: dissociation of effects on ionic current and gating current. Biophys J 2005; 88:211-223.